Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avalo Therapeutics ( (AVTX) ) has provided an announcement.
On April 26, 2026, Avalo Therapeutics entered into a Milestone Buyout Option and Amendment Agreement tied to its March 2024 acquisition of AlmataBio, Inc. The deal restructures a previously agreed $15 million contingent milestone payment that was to be triggered upon dosing the first patient in a Phase 3 trial.
Under the new arrangement, Avalo will pay $2.25 million to former AlmataBio securityholders within five business days of the effective date. It then has a 90-day option to pay an additional $5.125 million in cash, stock, or a mix, to fully settle the milestone, or otherwise remain liable for a $12.75 million payment when the Phase 3 dosing milestone is reached.
The modification, disclosed in an April 28, 2026 press release, gives Avalo greater flexibility in managing near- and medium-term cash outflows linked to its pipeline. The structure may reduce future milestone obligations if the company elects the buyout, potentially improving balance sheet visibility while preserving its strategic focus on advancing IL-1β-based therapies.
The most recent analyst rating on (AVTX) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Avalo Therapeutics stock, see the AVTX Stock Forecast page.
Spark’s Take on AVTX Stock
According to Spark, TipRanks’ AI Analyst, AVTX is a Neutral.
The score is primarily held back by very weak financial performance (minimal/declining revenue, large losses, and significant cash burn). Technical signals also lean bearish with the stock below key moving averages and a negative MACD. A positive offset comes from a notable pipeline milestone (Phase 2 enrollment complete with Q2 2026 data), but it does not fully counterbalance the current financial and momentum risks.
To see Spark’s full report on AVTX stock, click here.
More about Avalo Therapeutics
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases. Its lead asset, abdakibart (AVTX-009), is in a Phase 2 trial for hidradenitis suppurativa, and the company is exploring additional indications with significant unmet medical need.
Average Trading Volume: 684,299
Technical Sentiment Signal: Sell
Current Market Cap: $371.9M
Learn more about AVTX stock on TipRanks’ Stock Analysis page.